Simultaneous Spectrophotometric Determination of Finasteride and Tadalafil in Recently FDA Approved Entadfi Capsules
July 2022
in “
BMC chemistry
”
TLDR The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
The study developed and validated two UV spectrophotometric methods for the simultaneous quantification of finasteride and tadalafil in Entadfi™ capsules, which treat benign prostatic hyperplasia. The methods, using second and first order derivatives, showed excellent linearity, sensitivity, and selectivity, with LOD values of 2.406 µg/mL and 0.876 µg/mL for finasteride and tadalafil, respectively, using the second derivative method, and 2.229 µg/mL and 0.815 µg/mL using the first derivative method. Both methods achieved mean percent recoveries of over 99% for both drugs, making them suitable for quality control in pharmaceutical formulations.